Vortioxetine for Post-COVID-19 Condition

NCT05047952 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

149

Enrollment

OTHER

Sponsor class

Conditions

Post-COVID-19 Condition
Post-COVID-19 Syndrome
Cognitive Impairment

Interventions

DRUG: Vortioxetine
DRUG: Placebo

Sponsor

Brain and Cognition Discovery Foundation